During the past decade, Innovent Biologics (suzhou) Co. , Ltd. conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Innovent Biologics (suzhou) Co. , Ltd." are "Advanced Solid Tumor" (1 trials) and "Neovascular Age-related Macular Degeneration" (1 trials). Many other conditions were trialed in "Innovent Biologics (suzhou) Co. , Ltd." in a lesser frequency.

Most popular intervention types in "Innovent Biologics (suzhou) Co. , Ltd." are "Drug" (2 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Aflibercept" (1 trials), "High dose IBI302" (1 trials), "IBI 360 Injection" (1 trials) and "Low dose IBI302" (1 trials). Other intervention names were less common.

The vast majority of trials in "Innovent Biologics (suzhou) Co. , Ltd." are 2 trials for "All" genders.

Currently, there are NaN active trials in "Innovent Biologics (suzhou) Co. , Ltd.". undefined are not yet recruiting, 1 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in Innovent Biologics (suzhou) Co. , Ltd., undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Innovent Biologics (suzhou) Co. , Ltd., 1 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".